Beta Bionics (BBNX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$119.0M

Revenue (quarter)

$32.0M

Revenue growth (year over year)

+37.76%

Gross profit (trailing twelve months)

$69.4M

Gross margin

58.31%

Net income (trailing twelve months)

−$73.0M

Net income (quarter)

−$23.4M

Net income growth (year over year)

−38.73%

Net margin

−61.32%

Return on equity

−26.16%

EPS (trailing twelve months)

−$1.60

Book value per share

$5.70

P/E (trailing twelve months)

—

Price to book

3.67

Debt to assets

12.32%

Payout ratio

—

Dividend yield

—

Company profile

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

• Is Beta Bionics (BBNX) profitable?

  No. Beta Bionics reported a net loss of $73.0M over the trailing twelve months.

• How much revenue does Beta Bionics (BBNX) make?

  Beta Bionics generated $119.0M in revenue over the trailing twelve months, up 37.76% year over year.

• How do I buy stock in Beta Bionics (BBNX)?

  BBNX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.